Halper Sadeh LLC, an investor rights law firm, announced on October 3, 2025, that it is investigating whether the sale of Mural Oncology plc to XOMA Royalty Corporation is fair to Mural shareholders. The acquisition proposes a base cash price of $2.035 per share, with a potential additional payment of up to $0.205 per share under certain conditions.
The investigation focuses on whether Mural and its board of directors fulfilled their fiduciary duties to shareholders. Specific concerns include whether the board obtained the best possible consideration for shareholders, if XOMA is underpaying for Mural, and if all material information necessary for shareholders to adequately assess and value the merger consideration has been disclosed.
On behalf of Mural shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief and benefits. This investigation introduces a layer of uncertainty to the previously announced acquisition, potentially impacting the timeline or terms of the transaction.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.